Cretostimogene Grenadenorepvec Yields Durable Responses in NMIBC


More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

The next steps for the BOND-003 trial (NCT04452591) involve the treatment extension phase and the addition of a papillary-only cohort.

The next steps for the BOND-003 trial (NCT04452591) involve the treatment extension phase and the addition of a papillary-only cohort.

More than three quarters of the population with high-risk BCG-unresponsive non–muscle-invasive bladder cancer (NMINC) had a complete response following treatment with cretostimogene grenadenorepvec, according to findings from the phase 3 BOND-003 trial (NCT04452591) presented during the 2023 Society of Urologic Oncology (SUO) Annual Meeting.1

“Based on central review, 75.7% (95% CI, 63-85) of patients reached a complete response at any time point. The responses were durable with 74.4% of the complete responses lasting for at least 6 months,” Mark Tyson, MD, MPH, a urologic oncologist at the Mayo Clinic, said when presenting the data.

To enroll in the BOND-003 trial, patients had to have pathologically confirmed high-risk NMIBC with CIS +/- Ta/T1 that is unresponsive to BCG treatment; an ECOG performance status of 0 to 2; and not be eligible for or refuse to receive a radical cystectomy. Patients were required to have all Ta/T1 disease resected prior to receiving treatment.

Overall, 116 patients with BCG-unresponsive high-risk NMIBC have been enrolled on the trial, and the efficacy data presented at the SUO meeting were from the interim analysis of the first 66 patients at a cutoff date of October 5, 2023.

The 66 patients comprised 50 males and 16 females. The median patient age was 73 years (range, 49-90). Eighty percent of patients were aged >65 years. Fifty-three patients (80%) had an ECOG performance status of 0 and 13 patients (20%) had an ECOG performance status of 1. The median number of prior BCG instillations was 14.4 (range, 7-14). Regarding staging, 2 patients had CIS with T1, 10 patients had CIS with Ta HG, and 54 patients had CIS.

In the study design, the oncolytic immunotherapy is administered beginning with a weekly induction regimen lasting 6 weeks. This is followed by 3 weekly maintenance instillations at months 3, 6, 9, 12, and 18. Patients who continue to have high-grade disease at 3 months are eligible to receive a re-induction regimen of 6 weeks of weekly cretostimogene grenadenorepvec.

Notably, data from the interim analysis showed that 31% of patients who did not respond to their first course of treatment were able to be salvaged with re-induction.

The primary end point of the trial is the rate of complete responses achieved at any time on study. Secondary end points include the complete response rate at 12 months, duration of response, progression-free survival, cystectomy-free survival, and safety.

The complete response rate at 3 months was 68.2% (n = 45) and the complete response rate at 6 months was 63.6% (n = 42).

The safety population included 112 patients. Most adverse events (AEs) were grade 1/2. The most common treatment-related AEs (TRAEs) were bladder spasm (20.5%), pollakiuria (16.1%), dysuria (14.3%), micturition urgency (11.6%), and hematuria (10.7%).

Two patients (1.8%) experienced grade 2 serious TRAEs and no patients had grade ≥3 TRAEs. There were no treatment-related discontinuations and no patient deaths.

The next steps for BOND-003 involve the treatment extension phase and the addition of a papillary-only cohort. The phase 3 PIVOT-006 study is also launching. This trial is comparing Transurethral Resection of Bladder Tumor (TURBT) followed by adjuvant cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with intermediate-risk NMIBC.

Tyson also noted that cretostimogene grenadenorepvec has received FDA Fast Track Designation for the treatment of patients with BCG-unresponsive CIS with or without Ta/T1 papillary disease.

Commenting on the findings in a press release, Trinity J. Bivalacqua, MD, PhD, professor of Urology and Oncology at the Perelman Center for Advanced Medicine, University of Pennsylvania, said, “The positive BOND-003 initial results demonstrate the impact of cretostimogene in BCG-unresponsive disease patients as a promising new monotherapy which may lead to profoundly meaningful non-surgical outcomes for those with recurrent bladder cancer. NMIBC has been a difficult disease to treat, and patients have often had no options except surgical removal of the bladder.”2


  1. Tyson M, Uchio E, Jong-Kil N, et al. First results from BOND-003, a Phase 3 study of intravesical Cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive Non-Muscle Invasive Bladder Cancer. Presented at: 2023 Society of Urologic Oncology Annual Meeting. November 28 – December 1, 2023; Washington, DC. LBA3396.
  2. CG Oncology. Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. Published online and accessed November 30, 2023.
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content